Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Mydecine Innovations Group ( (TSE:NVRS) ) is now available.
Noveris Health Sciences Inc., a biotech firm specializing in next-generation psychedelic-based treatments for mental health conditions such as nicotine addiction and PTSD, leverages advanced drug discovery platforms, multinational teams, and partnerships with top specialists to address areas of significant unmet medical need. The company announced that Joshua Bartch has resigned as director, president, and CEO, and has been succeeded in all three roles by Jason Birmingham, previously chief strategy officer, marking a leadership transition that could shape its strategic direction and execution of its drug development pipeline.
More about Mydecine Innovations Group
Noveris Health Sciences Inc. is a biotechnology company focused on developing innovative medications and therapies for mental health disorders, including nicotine addiction and post-traumatic stress disorder. Its strategy combines advanced drug discovery technology, a global research infrastructure, and collaborations with leading specialists to advance next-generation psychedelic medicines with strong clinical and regulatory expertise.
Average Trading Volume: 2,891
Technical Sentiment Signal: Sell
Current Market Cap: C$407.6K
For detailed information about NVRS stock, go to TipRanks’ Stock Analysis page.